Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. May 6, 2015; 4(2): 245-253
Published online May 6, 2015. doi: 10.5527/wjn.v4.i2.245
Published online May 6, 2015. doi: 10.5527/wjn.v4.i2.245
Treatment of hypogonadotropic male hypogonadism: Case-based scenarios
Lindsey E Crosnoe-Shipley, Osama O Elkelany, Cyrus D Rahnema, Edward D Kim, Department of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, United States
Author contributions: Crosnoe-Shipley LE, Elkelany OO, Rahnema CD and Kim ED equally contributed to the manuscript.
Conflict-of-interest: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Edward D Kim, MD, Department of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine, 1928 Alcoa Highway, Suite 222, Knoxville, TN 37920, United States. ekim@utmck.edu
Telephone: +1-865-3059254 Fax: +1-865-3059716
Received: June 19, 2014
Peer-review started: June 21, 2014
First decision: August 14, 2014
Revised: December 27, 2014
Accepted: January 15, 2015
Article in press: January 19, 2015
Published online: May 6, 2015
Processing time: 322 Days and 18.3 Hours
Peer-review started: June 21, 2014
First decision: August 14, 2014
Revised: December 27, 2014
Accepted: January 15, 2015
Article in press: January 19, 2015
Published online: May 6, 2015
Processing time: 322 Days and 18.3 Hours
Core Tip
Core tip: Symptomatic hypogonadism is both a common and growing health issue. Our four case-based scenarios assess different treatment options for hypogonadotropic male hypogonadism such as clomiphene citrate, human chorionic gonadotropin, and anastrozole. Furthermore, we provide clinical recommendations that can help physicians when confronted with situations such as the ones presented in this article.